TrialClinical pharmacology and therapeutics2026

Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32-Week Randomized Phase 1b Multiple Ascending-Dose Trial.

Dave Singh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.